측방유동분석법 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 기술별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Lateral Flow Assays Market Size, Share & Trends Analysis Report By Product, By Application, By Technique, By End-use, By Region, And Segment Forecasts, 2026 - 2033

US $ 5,950 ￦ 8,615,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,062,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,958,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

측방유동분석법 시장 개요

세계의 측방유동분석법(LFA) 시장 규모는 2025년에 약 101억 7,000만 달러로 추정되며, 2033년에 174억 4,000만 달러에 달할 것으로 예측됩니다.

2026년부터 2033년까지 CAGR 7.41%로 성장할 것으로 예상되며, 이는 특히 현장 진료(POC) 및 가정용 검사 애플리케이션에서 신속하고 비용 효율적인 진단 솔루션에 대한 수요가 증가하고 있기 때문으로 분석됩니다. 감염병은 여전히 전 세계 보건 문제 중 하나입니다.

감염병은 여전히 전 세계 보건 문제 중 하나입니다. 2025년에는 새로운 감염병의 위협이 발생하여 신속진단키트(LFA)의 필요성이 더욱 강조되었습니다. 루이지애나주에서는 감염된 동물을 다루는 작업자의 보호장비 미착용과 관련된 조류인플루엔자 A형(H5N1) 사망 사례가 보고되었습니다. 미국 질병예방통제센터(CDC)는 2024년 67건의 H5N1 인체 감염 사례를 확인했으며, 이 중 40건은 젖소 노출, 23건은 가금류 농장 관련 사례였습니다. 영국은 2025년 위험 완화책으로 H5 백신 500만 회분 확보로 대응했습니다. 2025년 2월, 아일랜드에서 처음으로 원숭이 수두 Clade I(기존에 아프리카에서 우세한 균주)에 의한 원숭이 수두 사례가 확인되었습니다. 동시에 우간다에서는 2025년 1월 에볼라출혈열 발생이 선언되었고, WHO는 2월까지 7명의 환자(사망자 1명)를 확인했습니다. 이러한 발생 사례는 전 지구적 상호연결성과 환경적 요인에 의한 감염증의 예측 불가능성을 보여줍니다.

전 세계적으로 전염병의 높은 확산은 시장 성장의 주요 촉진요인으로 작용하고 있습니다. 이러한 질병들은 증가하는 사망률을 억제하기 위해 효율적인 치료를 실현할 수 있는 새로운 진단 기술을 필요로 합니다. 특히 COVID-19 팬데믹으로 인해 신속하고 접근 가능한 진단 도구의 필요성이 부각되면서 LFA(신속 항원 검사)에 대한 수요가 급증했습니다. COVID-19 외에도 새로운 감염병의 위협이 나타나고 있습니다. 예를 들어, 2025년 미국 루이지애나주에서 고병원성 조류인플루엔자 A(H5N1) 바이러스 감염으로 인한 사망자가 발생했습니다. 개인보호장비를 사용했지만, 그 효과가 미흡한 것으로 알려져 있습니다. 미국 질병예방통제센터(CDC)에 따르면 일반인의 위험은 낮지만, 감염된 동물과 밀접하게 접촉하는 농업 종사자, 수의사, 야생동물 시설 직원 등은 여전히 높은 위험에 노출되어 있다고 합니다. 2024년에는 67건의 조류인플루엔자 인체 감염 사례가 보고되었으며, 이 중 40건은 젖소 노출과 관련이 있고 23건은 가금류 사육장과 관련이 있습니다. 이에 따라 영국은 2025년의 잠재적 위험 감소를 위해 H5 백신 500만 회 분량을 미리 확보했습니다.

기술의 발전으로 측방유동분석법의 성능과 용도가 향상되었습니다. 민감도 및 특이도 향상, 다중화 기술, 스마트폰 앱 및 클라우드 연결 장치를 통한 디지털 응용 등이 포함됩니다. 후자의 발전으로 인해 측면 흐름 장치는 감염 탐지 이외의 분야(임신 검사, 심장병 모니터링, 수의학 진단, 환경 검사, 식품 안전, 기타)에서도 활용될 수 있게 되었습니다. 이러한 발전의 일환으로 Abingdon Health plc(영국)는 측면 흐름 시장의 주요 기업으로 자리매김했습니다. 2024년 5월, Abingdon Health plc는 Boots의 자체 브랜드 타액 기반 임신 자가진단 키트를 영국 내 및 Salignostics, Crest Medical을 통해 온라인 판매를 시작했습니다. 이 제품은 기존 소변 검사 방식의 임신 검사에서 비침습적 타액 검사로의 기술적 전환을 의미하며, 사용자의 편의성과 접근성을 높인 제품입니다. 제품 출시와 더불어 이 획기적인 제품 혁신은 Boots의 자체 브랜드 라인에 타액 임신 자가 테스트 키트를 채택한 최초의 기업으로서 Abingdon Health와 Boots의 전략적 제휴를 더욱 강화할 수 있는 계기가 되었습니다. 이러한 발전은 생명공학 혁신, 소비자 건강, 전략적 제휴가 세계 측방유동분석법 산업의 방향성에 지속적으로 영향을 미치고 있음을 보여줍니다.

목차

제1장 측방유동분석법 시장 : 조사 방법과 범위

제2장 측방유동분석법 시장 : 주요 요약

• 시장 개요
• 제품 개요
• 용도 개요
• 기술 개요
• 최종 용도 개요
• 경쟁 구도 개요

제3장 측방유동분석법 시장 변수, 동향, 범위

• 시장 세분화와 범위
• 시장 계통 전망
  • 상부 시장 전망
  • 관련·보조 시장 전망
• 시장 역학
• Porter's Five Forces 분석
• PESTLE 분석

제4장 측방유동분석법 시장 : 제품별, 추정·동향 분석

• 측방유동분석법 시장 : 제품 변동 분석
• 키트와 시약
• 측류 리더
  • 벤치탑 리더
  • 디지털 리더

제5장 측방유동분석법 시장 : 용도별, 추정·동향 분석

• 측방유동분석법 시장 : 용도 변동 분석
• 임상 검사
  • 감염증 검사
  • 심장 마커 검사
  • 임신·불임 검사
  • 콜레스테롤 검사/지질 프로파일
  • 약제 남용 검사
  • 기타 임상 검사
• 수의료적 진단
• 식품 안전·환경 검사
• 의약품 개발·품질 검사

제6장 측방유동분석법 시장 : 기술별, 추정·동향 분석

• 측방유동분석법 시장 : 기술 변동 분석
• 샌드위치법
• 경쟁 분석법
• 다중 검출 분석법

제7장 측방유동분석법 시장 : 최종 용도별, 추정·동향 분석

• 측방유동분석법 시장 : 최종 용도 변동 분석
• 병원·클리닉
• 진단 실험실
• 재택의료
• 제약 바이오테크놀러지 기업
• 기타

제8장 측방유동분석법 시장 : 지역별, 추정·동향 분석

• 측방유동분석법 시장 점유율(지역별, 2025년과 2033년, 100만 달러)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제9장 경쟁 구도

• 주요 시장 진입 기업의 최근 동향과 영향 분석
• 기업 분류
• 기업 히트맵 분석
• 기업 개요
  • Abbott
  • Bio-Rad Laboratories, Inc
  • Siemens Healthineers AG
  • BIOMERIEUX
  • BD
  • QIAGEN
  • QuidelOrtho Corporation
  • F. Hoffmann-La Roche
  • DH Life Sciences, LLC.
  • Quest Diagnostics

KSM

영문 목차

영문목차

Lateral Flow Assays Market Summary

The global lateral flow assays (LFA) market size was estimated at approximately USD 10.17 billion in 2025 and is projected to reach USD 17.44 billion by 2033, growing at a CAGR of 7.41% from 2026 to 2033, driven by the increasing demand for rapid and cost-effective diagnostic solutions, particularly in Point-of-Care (POC) and home-testing applications. Infectious diseases remain one of the main global health challenges.

Infectious diseases remain one of the main global health challenges. In 2025, new infectious disease threats have emerged, further underscoring the need for LFAs. In Louisiana, a fatal case of avian influenza A (H5N1) was reported, linked to inadequate protective equipment among workers handling infected animals. The CDC noted 67 human cases of H5N1 in 2024, with 40 cases tied to dairy cattle exposure and 23 to poultry farms. The UK responded by securing 5 million doses of an H5 vaccine to mitigate risks in 2025. In February 2025, Ireland confirmed its first case of mpox caused by monkeypox clade I, a strain previously dominant in Africa. Simultaneously, Uganda declared an Ebola outbreak in January 2025, with the WHO confirming seven cases, including one fatality, by February. These outbreaks illustrate the unpredictable nature of infectious diseases, driven by global interconnectivity and environmental factors.

The high prevalence of infectious diseases worldwide has been a major driver for the market growth. These diseases necessitate novel diagnostic techniques for efficient treatment to stop the rising mortality rate. The COVID-19 pandemic, in particular, highlighted the need for rapid and accessible diagnostic tools, leading to a surge in demand for LFAs. Beyond COVID-19, other infectious threats have emerged. For instance, in 2025, a highly pathogenic avian influenza A (H5N1) virus infection resulted in a fatality in Louisiana, USA, despite the use of personal protective equipment that was deemed inadequate. According to the Centers for Disease Control and Prevention (CDC), while the general public faces a low risk, individuals working closely with infected animals-such as farmers, veterinarians, and wildlife facility staff-remain highly vulnerable. In 2024, 67 human cases of avian influenza were reported, with 40 linked to exposure to dairy cattle and 23 associated with poultry farms. In response, the UK proactively secured 5 million doses of the H5 vaccine to mitigate potential risks in 2025.

Technological advancements now allow for improved performance and use of lateral flow assays, including advances in sensitivity, specificity, multiplexing, and digital applications via smartphone apps and cloud-connected devices. The latter advances have meant that lateral flow devices may be used in areas outside infectious disease detection, including pregnancy testing, heart disease monitoring, veterinary diagnostics, environmental testing, and food safety. As part of the advances above, Abingdon Health plc (UK) has established itself as a key player in the lateral flow market. In May 2024, Abingdon Health plc launched Boots' own-brand saliva-based pregnancy self-test to the UK and online via Salignostics and Crest Medical. This product represents a technological shift from traditional urine-based pregnancy tests to non-invasive saliva testing, thus providing greater convenience and accessibility for the user. In addition to launching the product, the significant advancement in product innovation provided an opportunity to further strengthen Abingdon Health's strategic partnership with Boots as the first company to adapt a saliva pregnancy self-test into Boots' own-brand range. These advances demonstrate how biotechnology innovation, consumer health, and strategic partnerships continue to influence the direction of the global lateral flow assays industry.

Global Lateral Flow Assays Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global lateral flow assays market report based on product, application, technique, end-use, and region:

• Product Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• Kits & Reagents
• Lateral Flow Readers
  • Digital/Mobile Readers
  • Benchtop Readers
• Application Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• Clinical Testing
  • Infectious Diseases Testing
  • COVID-19 Testing
  • Mosquito Borne Disease Testing
  • Malaria Testing
  • Dengue Testing
  • Zika Testing
  • Chikungunya Testing
  • Others
  • Influenza Testing
  • Sexually Transmitted Infection Testing
  • HIV Testing
  • HPV Testing
  • Chlamydia Testing
  • Gonorrhea Testing
  • Syphilis Testing
  • Others
  • Hepatitis
  • Tuberculosis
  • Others
  • Cardiac Marker Testing
  • Troponin I and T Testing
  • CK-MB Testing
  • BNP and NT-proBNP Testing
  • Myoglobin Testing
  • D-Dimer Testing
  • Others
  • Pregnancy & Fertility Testing
  • Pregnancy Testing
  • Fertility Testing
  • Cholesterol Testing/Lipid Profile Testing
  • Drugs of Abuse Testing
  • Others
• Veterinary Diagnostics
• Food safety & Environment Testing
• Drug Development & Quality Testing
• Technique Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• Sandwich Assays
• Competitive Assays
• Multiplex Detection Assays
• End-use Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Home Care
• Pharmaceutical & Biotechnology Companies
• Others
• Regional Outlook (Volume, Thousands; Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Lateral Flow Assays market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Application Segment
    • 1.1.1.3. Technique Segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Lateral Flow Assays Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product Snapshot
• 2.3. Application Snapshot
• 2.4. Technique Snapshot
• 2.5. End Use Snapshot
• 2.6. Competitive Landscape Snapshot

Chapter 3. Lateral Flow Assays Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Increasing prevalence of infectious diseases
    • 3.3.1.2. Technological advancements in lateral flow
    • 3.3.1.3. Growing adoption in homecare settings
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Stringent Regulations
• 3.4. Porter's Five Forces Analysis
• 3.5. PESTLE Analysis

Chapter 4. Lateral Flow Assays Market: Product Estimates & Trend Analysis

• 4.1. Lateral Flow Assay Market: Product Movement Analysis
• 4.2. Kits & Reagents
  • 4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 4.3. Lateral Flow Readers
  • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 4.3.2. Benchtop Readers
    • 4.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 4.3.3. Digital Readers
    • 4.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)

Chapter 5. Lateral Flow Assays Market: Application Estimates & Trend Analysis

• 5.1. Lateral Flow Assay Market: Application Movement Analysis
• 5.2. Clinical Testing
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 5.2.2. Infectious Disease Testing
    • 5.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.2. COVID-19
      • 5.2.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.3. Mosquito Borne Disease Testing
      • 5.2.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.3.2. Malaria Testing
        • 5.2.2.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.3.3. Dengue Testing
        • 5.2.2.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.3.4. Zika Testing
        • 5.2.2.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.3.5. Chikungunya Testing
        • 5.2.2.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.3.6. Others
        • 5.2.2.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.4. Influenza Testing
      • 5.2.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.5. Sexually Transmitted Infection Testing
      • 5.2.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.5.2. HIV Testing
        • 5.2.2.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.5.3. HPV Testing
        • 5.2.2.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.5.4. Chlamydia Testing
        • 5.2.2.5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.5.5. Gonorrhea Testing
        • 5.2.2.5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.5.6. Syphilis Testing
        • 5.2.2.5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
      • 5.2.2.5.7. Other STI Testing
        • 5.2.2.5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.6. Hepatitis
      • 5.2.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.7. Tuberculosis
      • 5.2.2.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.2.8. Other Infectious Diseases
      • 5.2.2.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 5.2.3. Cardiac Marker Testing
    • 5.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.3.2. Troponin I and T Testing
      • 5.2.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.3.3. CK-MB Testing
      • 5.2.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.3.4. BNP and NT-Probnp Testing
      • 5.2.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.3.5. Myoglobin Testing
      • 5.2.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.3.6. D-Dimer Testing
      • 5.2.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.3.7. Other Cardiac Marker Tests
      • 5.2.3.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 5.2.4. Pregnancy & Fertility Testing
    • 5.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.4.2. Pregnancy Testing
      • 5.2.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
    • 5.2.4.3. Fertility Testing
      • 5.2.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 5.2.5. Cholesterol Testing/Lipid Profile
    • 5.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 5.2.6. Drugs of Abuse Testing
    • 5.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 5.2.7. Other Clinical Tests
    • 5.2.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 5.3. Veterinary Diagnostics
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 5.4. Food Safety & Environment Testing
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 5.5. Drug Development & Quality Testing
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)

Chapter 6. Lateral Flow Assays Market: Technique Estimates & Trend Analysis

• 6.1. Lateral Flow Assay Market: Technique Movement Analysis
• 6.2. Sandwich Assays
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 6.3. Competitive Assays
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 6.4. Multiplex Detection Assays
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)

Chapter 7. Lateral Flow Assays Market: End Use Estimates & Trend Analysis

• 7.1. Lateral Flow Assay Market: End Use Movement Analysis
• 7.2. Hospitals & Clinics
  • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 7.3. Diagnostic Laboratories
  • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 7.4. Home Care
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 7.5. Pharmaceutical & Biotechnology Companies
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 7.6. Other End Use
  • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)

Chapter 8. Lateral Flow Assays Market: Regional Estimates & Trend Analysis

• 8.1. Lateral Flow Assay Market Share, By Region, 2025 & 2033, USD Million
• 8.2. North America
  • 8.2.1. North America Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Reimbursement Scenario
    • 8.2.2.5. U.S. Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Reimbursement Scenario
    • 8.2.3.5. Canada Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Competitive Scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Reimbursement Scenario
    • 8.2.4.5. Mexico Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 8.3. Europe
  • 8.3.1. Europe Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. UK Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Germany Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. France Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Reimbursement Scenario
    • 8.3.5.5. Italy Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Reimbursement Scenario
    • 8.3.6.5. Spain Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Reimbursement Scenario
    • 8.3.7.5. Denmark Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Reimbursement Scenario
    • 8.3.8.5. Sweden Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Reimbursement Scenario
    • 8.3.9.5. Norway Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Japan Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. China Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. India Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Australia Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.4.6. South Korea
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. South Korea Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario
    • 8.4.7.5. Thailand Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 8.5. Latin America
  • 8.5.1. Latin America Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Brazil Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Argentina Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
• 8.6. Middle East and Africa
  • 8.6.1. Middle East and Africa Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. South Africa Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. Saudi Arabia Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. UAE Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Kuwait Lateral Flow Assay Market Estimates and Forecasts, 2021 - 2033 (USD Million, Volume, in thousands)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
  • 9.4.1. Abbott
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Bio-Rad Laboratories, Inc
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Siemens Healthineers AG
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. BIOMERIEUX
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. BD
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. QIAGEN
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. QuidelOrtho Corporation
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. F. Hoffmann-La Roche
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. DH Life Sciences, LLC.
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Quest Diagnostics
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives

관련자료